COR vs MCK: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COR and MCK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COR and MCK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Cencora buys pharmaceuticals from manufacturers and delivers them to pharmacies, hospitals, physician practices and clinics, taking a fee measured in fractions of a percent on each transaction. Roughly 90 percent of revenue sits in the U.S. Healthcare Solutions segment, where specialty products (oncology drugs, biologics, cell and gene therapies) carry better economics than traditional generics and now anchor the growth rate. International Healthcare Solutions covers distribution and specialty logistics across Europe and Canada, and the smaller Other segment holds MWI Animal Health and Brazil's Profarma. The company employs roughly 47,000 people and was known as AmerisourceBergen until August 2023.

Full COR guide

McKesson Corporation is a healthcare-services and pharmaceutical-distribution company, one of the "Big Three" US drug wholesalers alongside Cencora (formerly AmerisourceBergen) and Cardinal Health that together handle the large majority of prescription drugs sold in the country. In fiscal 2026 the company reported roughly $337 billion in revenue, the bulk of it from its North American Pharmaceutical segment, which sources, warehouses, and delivers branded, generic, and specialty medicines to pharmacies, health systems, and providers. Because distribution is a scale game with very low margins, McKesson competes on logistics efficiency, breadth of contracts, and reliability rather than pricing power on the drugs themselves.

Full MCK guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• COR drivers: Specialty volume, not overall drug volume; Moving downstream into provider services.
• MCK drivers: Defensive, volume-driven distribution core; Specialty and oncology services mix-shift.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Customer concentration is the sharpest exposure: a small number of relationships, including Walgreens and Evernorth, account for a large share of revenue, so a contract renegotiation or loss would be felt immediately. For MCK, the central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results.

Pick COR if you believe its drivers more; MCK if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the COR and MCK guides.

COR. The gap between a ~$333 billion top line and a ~$62 billion market value is the whole point of the business model, and reading the revenue figure as a measure of scale in the usual sense will mislead. Cencora keeps roughly three cents of gross profit per dollar of product it moves and about one cent of operating profit, so valuation is set off earnings and free cash flow rather than any revenue multiple. At recent prices the shares trade around 18 times the midpoint of fiscal 2026 adjusted EPS guidance, which sits close to where McKesson and Cardinal Health have traded through the same stretch.

MCK. All figures are approximate, tied to the asOf date, and blend fiscal-year and quarterly disclosures; verify live numbers before acting. Note McKesson reports on a fiscal year ending in March, so "fiscal 2026" spans calendar 2025 into early 2026. Because distribution revenue is enormous but low-margin, revenue-based multiples are misleading here: analysts focus on adjusted EPS growth, free cash flow, and the mix-shift toward higher-margin services.

Headline figures (approximate, August 2026): COR shows revenue (ttm) ~$333 billion, fiscal q3 2026 revenue ~$84.8 billion, up ~5% year over year, adjusted diluted eps (fy2026 guidance) ~$17.75 to ~$17.95, market capitalization ~$62 billion; MCK shows revenue (fy2026) ~$337 billion, the vast majority from North American pharmaceutical distribution (approximate; verify live), segment profit mix North American Pharmaceutical ~$3.5B adjusted operating profit; Oncology & Multispecialty ~$1.4B; Prescription Technology ~$1.1B (approximate), margin profile Very low overall (low-single-digit operating margin) because distribution dominates revenue; services segments carry much higher margins, earnings trend Management raised full-year adjusted EPS guidance multiple times through fiscal 2026 (qualitative; confirm latest figures).

COR and MCK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined COR and MCK exposure against your real portfolio. It is not an investment adviser.